CA Patent

CA3158321A1 — Therapeutic combinations of acalabrutinib and capivasertib to treat b-cell malignancies

Assigned to AstraZeneca AB · Expires 2021-05-14 · 5y expired

What this patent protects

The present disclosure relates, in general, to therapeutic combinations of acalabrutinib and capivasertib, and to corresponding methods of treatment, pharmaceutical compositions, and kits.

USPTO Abstract

The present disclosure relates, in general, to therapeutic combinations of acalabrutinib and capivasertib, and to corresponding methods of treatment, pharmaceutical compositions, and kits.

Drugs covered by this patent

Patent Metadata

Patent number: CA3158321A1
Jurisdiction: CA
Classification: —
Expires: 2021-05-14
Drug substance claim: No
Drug product claim: No
Assignee: AstraZeneca AB
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.